Cabozantinib is a newly developed small molecule inhibitor of the tyrosine kinases c-MET and VEGFR2 that is used to treat medullary thyroid cancer[41] and a first-line treatment for advanced RCC[42], amongst other cancer types. This evidence concerns the gene KDR and cancer.